CLAIMS

1. A composition for use in treatment or prophylaxis of a preterm infant, comprising:
    - IGF-1 and IGFBP-3 and polysorbate surfactant selected from polysorbate 20 and polysorbate 80 at a concentration of 0.0025% and 0.0075% v/v to be administered at a dose of 200 to 500 μg/Kg/24hours by continuous intravenous infusion, and
    - a compatible composition to be co-administered via the same IV line selected from the group comprising:
        i. Fentanyl citrate at a dose selected from 0.5, 2 and 5 μg/Kg/h,
        ii. Midazolam hydrochloride at a dose selected from 20 and 60 μg/Kg/h,
        iii. morphine sulfate at a dose selected from 5, 10 and 50 μg/Kg/h, and
        iv. norepinephrine bitartrate at a dose 0.05 μg/Kg/min,

    wherein the combination is physically and chemically stable and the pH of the admixture is 5.5 +/- 0.3.

2. A composition for use according to claim 1, wherein the composition is not co-administered with a composition selected from amikacin, ampicillin, dobutamine, dopamine, flurosemide, meropenem, high dose of norepinephrine, penicillin G, vancomycin at concentrations of over 5mg/ml and combinations thereof, such as 2, 3, 4 or more thereof.

3. A composition for use according to claims 1 or 2, wherein the IGF-1 and IGFBP-3 is to be administered in combination with fentanyl.

4. A composition for use according to claims 1 or 2, wherein the IGF-1 and IGFBP-3 is to be administered in combination with midazolam.

5. A composition for use according to claims 1 or 2, wherein the IGF-1 and IGFBP-3 is to be administered in combination with morphine.

6. A composition for use according to claims 1 or 2, wherein the IGF-1 and IGFBP-3 is to be administered in combination with a low dose of norepinephrine.

7. A composition for use according to any one of claims 2 to 6, wherein the non-co-administered composition is to be administered by a different IV line or by a different route of administration, such as intramuscular administration.

8. A composition for use according to any one of claims 2 to 6, wherein the non-co-administered composition is omitted completely.

9. A composition for use according to any preceding claim, wherein the preterm infants are 23 to 34 weeks post gestation, when treatment is initiated.

10. A composition for use according to any preceding claim, wherein the preterm infants are to be administered IGF-1 and IGFBP-3 by infusion for at least 1 week, for example 2 to 6 weeks, such as 2, 3, 4, 5 or 6 weeks.

11. A composition for use according to claim 10, wherein the infusion is to be initiated within 24 hours of birth, for example within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 16, 17, 18, 19, 20, 21, 22, 23 and 24 hours of birth, in particular within 1 hour of birth.

12. A composition for use according to any one of claims 1 to 11, where the composition comprises equimolar amounts of IGF-1 and IGFBP-3.

13. A composition for use according to any preceding claim, wherein the osmolarity is 300 ± 30 mOsmol/kg.